In the Matter of the Application of William B. Dickinson and Bernard L. Zenitz

299 F.2d 954, 49 C.C.P.A. 951
CourtCourt of Customs and Patent Appeals
DecidedMarch 22, 1962
DocketPatent Appeal 6751
StatusPublished
Cited by8 cases

This text of 299 F.2d 954 (In the Matter of the Application of William B. Dickinson and Bernard L. Zenitz) is published on Counsel Stack Legal Research, covering Court of Customs and Patent Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In the Matter of the Application of William B. Dickinson and Bernard L. Zenitz, 299 F.2d 954, 49 C.C.P.A. 951 (ccpa 1962).

Opinion

MARTIN, Judge.

This is an appeal from a decision of the Board of Appeals of the United States Patent Office affirming the examiner’s rejection of claims 1 to 5, all of the claims of appellants’ application for a patent.

The application was filed November 12, 1957 and relates to certain piperidine carboxylic acid derivatives and to a process of preparing them. The compounds claimed are disclosed to be “physiologically active” and “useful as analgesics and narcotics.” Claim 1 is representative of the appealed claims and reads as follows:

“1. A compound selected from the class consisting of ethyl 1-methyl-4-phenylisonipecotate N-oxide free base and ethyl 1-methly-4-phenylisonipecotate N-oxide acid addition salt of a pharmacologically acceptable acid.”

Appealed claims 1, 2 and 3 were copied from patent No. 2,785,168 which had issued to Tiffany on March 12, 1957 on an application filed August 16, 1955. Ap *955 pealed claim 4 recites a specific compound within the scope of claim 3 and disclosed but not claimed as a species by Tiffany. Appealed claim 5 recites a process for preparing the compound of claim 2. This process is disclosed but not claimed by Tiffany.

The issues in this case relate to the requirements and application of 35 U.S.C. § 135 and Rules 204(b) and 131, 35 U.S.C. Appendix. 1

When appellants’ application was filed, it was accompanied by a request that an interference be declared between the application and the Tiffany patent. As required by the portion of rule 204(b) before the semicolon therein, appellants also filed with their application an affidavit stating that they had made the claimed invention prior to the filing date of the Tiffany patent.

The examiner refused to declare an interference, requiring in effect a second affidavit in accord with the portion of Rule 204(b) after the semicolon therein. Such an affidavit was submitted. Relative to the utility of the claimed compound, this se’cond affidavit stated:

“We submitted the sample of ethyl l-methyl-4-phenylisonipeeotate N-ox *956 ide, prepared as described above, for testing in the biological laboratories for pharmacological properties with the expectation that it would have analgesic activity;”

Thereupon the examiner stated in pertinent part:

“Since the affidavit does not disclose a date as to when ethyl 1-methyl-4-phenylisonipecotate was found to have analgesic activity nor whether such activity in the compound was discovered prior to August 16,' 1955, the requested interference will not be declared.”

At this point, the appealed claims stood rejected in view of the Tiffany patent and the case was appealed to the Board of Appeals.

Subsequently appellants submitted a third affidavit which stated in relevant part:

“ * * * the utility of ethyl 1-methyl - 4 - phenylisonipecotate N-oxide hydrochloride [claim 4] as an analgesic agent was obvious to us prior to the time we made the compound and prior to August 16, 1955, the filing date of Tiffany, U. S. Patent 2,785,168;
“ * * * the utility was obvious to us at the time we submitted the compound for testing which was prior to August 16, 1955.”

The second and third affidavits were accompanied by various laboratory notebook exhibits and supplementary affidavits.

The position of the examiner appears to have been that since the Rule 204(b) affidavits must be “of the nature specified in rule 131,” the requirements of the latter rule must be satisfied. The examiner held that a “reduction to practice” within the meaning of Rule 131(b) includes establishment of the utility of the claimed compound and that the affidavits do not show reduction to practice in this regard. In particular, the examiner noted that even though appellants had stated in the third affidavit that the analgesic utility was obvious, the second affidavit shows that a compound had been submitted for testing. In other words, the examiner appears to have found an inconsistency between the alleged obviousness of utility and the fact that tests were made.

“6. Duties of Commissioner “ * * * He may, subject to the approval of the Secretary of Commerce, establish regulations, not inconsistent with law, for the conduct of proceedings in the Patent Office.”

The board affirmed the examiner, finding support in Blicke v. Treves, 241 F.2d 718, 44 CCPA 753, for its position that “the instant compounds are not of such a nature that they were reduced to practice merely by making them.”

Two other issues were raised below by appellants. Before the case was considered by the Board of Appeals, appellants urged by petition to the Commissioner, first, that there is no statutory basis for that portion of Rule 204(b) which follows the semicolon therein since the affidavit required by that portion relates to a question of priority which “shall be determined by a board of patent interferences.” 2 In other words, appellants urged in their petition to the Commissioner that the final portion of Rule 204 (b) is inconsistent with 35 U.S.C. § 135, and that the Commissioner has exceeded the rule-making authority given him by 35 U.S.C. § 6. 3

Appellants also urged as a second point in their petition to the Commissioner as follows:

“Assuming, arguendo, statutory basis exists for Rule 204(b) and that an applicant can be required to present facts which would prima facie entitled him to an award of priority relative to the filing date of a patentee: It is submitted the determination of whether such facts as may be presented in a case are suffi *957 cient on the question of priority-rests with a board of patent interferences and is not within the jurisdiction of a Primary Examiner.”

The Supervisory Examiner, as delegate of the Commissioner, dismissed this petition because it was “addressed to nonpetitionable matters.” On petition for reconsideration, the Assistant Commissioner, as a further delegate of the Commissioner, ruled that appellants’ contention that the last clause of Rule 204(b) is invalid “is without merit” on the ground that 35 U.S.C. § 135 “vests the Commissioner with the authority to determine whether or not an interference exists and whether an interference proceeding should be instituted,” and that the criteria of Rule 204 represent “a valid and reasonable exercise of that power.”

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Estate of Simkins v. Commissioner
1978 T.C. Memo. 338 (U.S. Tax Court, 1978)
Golota v. Strom
489 F.2d 1287 (Customs and Patent Appeals, 1974)
Schwab v. Pittman
451 F.2d 637 (Customs and Patent Appeals, 1971)
Samuel S. Kistler v. Neill Weber
412 F.2d 280 (Customs and Patent Appeals, 1969)
Application of Andrew John Manson
333 F.2d 234 (Customs and Patent Appeals, 1964)

Cite This Page — Counsel Stack

Bluebook (online)
299 F.2d 954, 49 C.C.P.A. 951, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-the-matter-of-the-application-of-william-b-dickinson-and-bernard-l-ccpa-1962.